Learn how patient-derived organoid co-cultures with T cells can form a powerful preclinical platform to evaluate the efficacy, specificity, and mechanism of action of bispecific antibodies
The client, developing bispecific T cell engager (BiTE) for solid tumor indications, required a preclinical system capable of accurately assessing both efficacy and safety of their lead candidate. Conventional 2D models lacked the complexity needed to evaluate tumor-selective killing and immune engagement within a human-relevant microenvironment. Specifically, they needed a translational in vitro immunotherapy model that could preserve tumor heterogeneity, reflect patient-specific antigen expression, and support functional co-culture with T cells to de-risk downstream in vivo studies and guide candidate optimization.
We applied our PDO–T cell co-culture platform to model antigen-specific immune engagement and cytotoxicity. Using matched tumor and normal NSCLC patient-derived organoids, we established co-cultures with primary T cells to assess the bispecific antibody’s ability to induce selective killing and activate T cells. The system enabled head-to-head comparison of on-target efficacy and potential off-tumor toxicity, with quantitative functional readouts – providing the client with translationally predictive data ahead of in vivo studies.
We designed an experiment with 3 key assays:
Leveraging our large living biobank, we suggested testing the expression of the tumor-associated antigen (TAA) in NSCLC tumor organoids and matched normal lung organoids. Using immunohistochemistry and flow cytometry data, we supported our client in selecting the most relevant organoid models.
Fig1: A) Representative images of IHC staining for the TAA in human tumor tissue and matched normal epithelium. B) Flow cytometry analysis shows expression levels of TAA in 3 pairs of matched normal and tumor patient-derived organoids
Flow cytometry confirmed expression of the TAA in both tumor and normal PDOs, with apparent enrichment in NSCLC tumor organoids. This ensured both specificity and the relevance of the chosen models for subsequent efficacy and toxicity testing.
The bispecific antibody induced significant killing of tumor PDOs when co-cultured with T cells. Normal PDOs were largely spared under identical conditions. No cell death occurred in the absence of T cells or when using a non-targeting BiTE, confirming both antigen specificity and T cell dependence.
Fig3: Day 2 quantification of cell death fluorescent signal in A) tumor and B) normal PDOs when exposed to a BiTE directed to a tumor-specific antigen. For organoid killing, staurosporine (STS) is used as positive control and medium only as negative control. T cell Trans activator is included as a control for T-cell activation (TnsA). In absence of T- cells, the tested BiTE (TnsA and nonspecific ab) is not able to induce PDO cell death.
IFN-γ secretion was significantly elevated in co-cultures treated with the targeted BiTE, indicating effective activation of T cells in response to TAA recognition on tumor PDOs.
This study demonstrated that the bispecific antibody elicited antigen-specific, T cell–dependent killing of NSCLC PDOs, with minimal off-tumor effects on matched normal organoids. Elevated IFN-γ secretion confirmed functional T cell engagement. The PDO–T cell co-culture system provided mechanistic insight into the bispecific’s efficacy, selectivity, and mode of action, supporting its progression toward in vivo validation. For bispecific antibody developers, this platform offers a translationally relevant, human-derived system to de-risk immunotherapeutic candidates early in development by modeling tumor–immune dynamics and off-tumor toxicity in vitro.
Connect to explore organoid–T cell co-culture testing for your candidates
